Biofrontera (DB:AI10) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

AI10 Panoramica delle azioni

A biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.

Informazioni sull'azienda

AI10 analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 25.42% all'anno

Negoziato a un buon valore rispetto ai pari e al settore

Analisi del rischio

Le azioni sono altamente illiquide

Non ha una capitalizzazione di mercato significativa ( €12M )

Gli azionisti sono stati diluiti nell'ultimo anno

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Biofrontera Inc. Concorrenti

Biofrontera

XTRA:B8FK

€14.5m

SynBiotic

DUSE:SBX

€29.5m

Apontis Pharma

XTRA:APPH

€54.0m

Cantourage Group

XTRA:HIGH

€62.4m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Biofrontera
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$9.74
Massimo di 52 settimane	US$25.00
Minimo di 52 settimane	US$7.26
Beta	0
1Variazione di 1 mese	0%
Variazione a 3 mesi	4.06%
Variazione di 1 anno	-51.30%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	-84.45%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	AI10	DE Pharmaceuticals	DE Mercato
7D	0%	-3.0%	-1.9%
1Y	-51.3%	-13.2%	12.3%

Ritorno vs Industria: AI10 ha avuto una performance inferiore rispetto al German Pharmaceuticals che ha registrato un rendimento -13.5 % nell'ultimo anno.

Rendimento vs Mercato: AI10 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 4.7 % nell'ultimo anno.

Volatilità dei prezzi

Is AI10's price volatile compared to industry and market?
AI10 volatility
AI10 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: AI10 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di AI10 nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2015	81	Hermann Luebbert	www.biofrontera-us.com

Biofrontera Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Biofrontera con la sua capitalizzazione di mercato?
AI10 statistiche fondamentali
Capitalizzazione di mercato	€11.35m
Guadagni(TTM)	-€21.44m
Ricavi(TTM)	€27.47m

0.4x

Rapporto P/S

-0.5x

Rapporto P/E

AI10 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
AI10 Conto economico (TTM)
Ricavi	US$29.05m
Costo del fatturato	US$14.97m
Profitto lordo	US$14.08m
Altre spese	US$36.75m
Guadagni	-US$22.67m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-16.57
Margine lordo	48.47%
Margine di profitto netto	-78.03%
Rapporto debito/patrimonio netto	15.4%

Come si è comportato AI10 nel lungo periodo?

Vedi performance storica e confronto

AI10 Panoramica delle azioni

Premi

Analisi del rischio

Biofrontera Inc. Concorrenti

XTRA:B8FK

€14.5m

DUSE:SBX

€29.5m

XTRA:APPH

€54.0m

XTRA:HIGH

€62.4m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Biofrontera Inc. to Report Q2, 2024 Results on Aug 14, 2024

Biofrontera Announces the Launch of A New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Biofrontera Inc. to Report Q1, 2024 Results on May 15, 2024

Biofrontera Inc., Annual General Meeting, Jun 12, 2024

Biofrontera Inc. to Report Q4, 2023 Results on Mar 15, 2024

Biofrontera Inc. announced that it has received $8 million in funding

Recent updates

Biofrontera Inc. to Report Q2, 2024 Results on Aug 14, 2024

Biofrontera Announces the Launch of A New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Biofrontera Inc. to Report Q1, 2024 Results on May 15, 2024

Biofrontera Inc., Annual General Meeting, Jun 12, 2024

Biofrontera Inc. to Report Q4, 2023 Results on Mar 15, 2024

Biofrontera Inc. announced that it has received $8 million in funding

Biofrontera Inc. announced that it expects to receive $8 million in funding

Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use

Nasdaq Determines to Grant Biofrontera Inc. an Extension of 180 Calendar Days from November 22, 2023 to Regain Compliance

Biofrontera Inc. has filed a Follow-on Equity Offering in the amount of $4.5 million.

Biofrontera Inc. to Report Q4, 2023 Results on Mar 06, 2024

Biofrontera Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Continued Listing Requirement Under Nasdaq Listing Rule 5550(b)(1)

Biofrontera Inc., Annual General Meeting, Dec 20, 2023

Biofrontera Inc. Reaffirms Revenue Guidance for the Full Year 2023

Biofrontera Inc. to Report Q3, 2023 Results on Nov 09, 2023

Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)

Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)

Biofrontera Inc. Affirms Guidance for 2023

Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-Pdt for the Treatment of Basal Cell Carcinoma

Biofrontera Inc. to Report Q2, 2023 Results on Aug 11, 2023

New minor risk - Profitability

Biofrontera Inc. Provides Preliminary Revenue Guidance for the Second Quarter, First Half and Full-Year of 2023

Biofrontera Inc. Appoints Heikki Lanckriet to Its Board of Directors

Biofrontera Announces 1-For-20 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Biofrontera Notifies Nasdaq Regarding its No Longer in Compliance with Nasdaq Listing Rule 5605(c)(2)(A)

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.33 profit in 1Q 2022)

Biofrontera Inc. Announces Resignation of Erica Monaco, Chief Executive Officer

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: US$0.024 loss per share (vs US$4.28 loss in FY 2021)

Less than half of directors are independent

Forecast breakeven date pushed back to 2024

Biofrontera Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Biofrontera Inc. to Launch Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

Forecast breakeven date moved forward to 2022

Less than half of directors are independent

Biofrontera Inc. Revises Revenue Guidance for the Year 2022

Biofrontera Inc. to Report Q3, 2022 Results on Nov 14, 2022

Biofrontera Inc., Annual General Meeting, Dec 12, 2022

Biofrontera Inc. Names Fred Leffler as Chief Financial Officer

Biofrontera Inc. Reports Preliminary Product Revenues for the Third Quarter and Nine Months Ended September 30, 2022

Biofrontera Inc. Appoints Gerard Digirolamo as National Sales Director

Second quarter 2022 earnings released: US$0.045 loss per share (vs US$0.46 loss in 2Q 2021)

Biofrontera Inc. Provides Earnings Guidance for the Fiscal Year of 2022

Biofrontera Inc. to Report Q2, 2022 Results on Aug 12, 2022

Biofrontera Inc. Provides Revenue Guidance for the Second Quarter and Six Months Ended June 30, 2022

Biofrontera Inc.(NasdaqCM:BFRI) dropped from Russell Microcap Value Index

Biofrontera Inc. Appoints Kevin D. Weber to the Nominating and Corporate Governance, Audit and Compensation Committees

Biofrontera Inc. Appoints Kevin D. Weber to the Nominating and Corporate Governance, Audit and Compensation Committees

Biofrontera Inc. announced that it has received $9.40068 million in funding

Biofrontera Inc. announced that it expects to receive $9.40225 million in funding

First quarter 2022 earnings released: EPS: US$0.33 (vs US$0.44 loss in 1Q 2021)

Biofrontera Inc. Re-Affirms Earnings Guidance for 2022

Biofrontera Inc. to Report Q1, 2022 Results on May 13, 2022

Less than half of directors are independent

Full year 2021 earnings released: US$4.28 loss per share (vs US$479 loss in FY 2020)

Forecast to breakeven in 2023

High number of new and inexperienced directors

Rendimenti per gli azionisti